Haleos Labs Limi

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE320X01016
NSEID: HALEOSLABS
BSEID: 540679
View on NSE | View on BSE

INR

1,258.80

-9.2 (-0.73%)

BSENSE

Jan 19

BSE+NSE Vol: 87

{
  "main_header": {
    "sid": 1002809,
    "name": "Haleos Labs Limi",
    "stock_name": "Haleos Labs Limi",
    "full_name": "Haleos Labs Limited",
    "name_url": "stocks-analysis/haleos-labs-limi",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,258.80",
    "chg": -9.2,
    "chgp": "-0.73%",
    "dir": -1,
    "prev_price": "1,268.00",
    "mcapval": "379.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540679,
    "symbol": "HALEOSLABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE320X01016",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "87 ",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/haleos-labs-limi-1002809-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Haleos Labs Limited is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-by-marketsmojo-3791805",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/HaleosLabsLimit_mojoScore_3791805.png",
        "date": "2026-01-14 10:10:37",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Haleos Labs Limited is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-by-marketsmojo-3779920",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/HaleosLabsLimit_mojoScore_3779920.png",
        "date": "2026-01-03 10:10:34",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-lower-circuit-amid-heavy-selling-pressure-3770563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/HaleosLabsLimit_stocks_hitting_lower_circuit_3770563.png",
        "date": "2025-12-26 11:00:15",
        "description": "Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals &amp; Biotechnology sector, faced intense selling pressure on 26 Dec 2025, hitting the lower circuit limit and registering one of the steepest single-day declines in recent times. The stock’s performance contrasted sharply with broader market indices and its sector peers, reflecting a wave of panic selling and unfilled supply on the trading floor."
      },
      {
        "title": "Haleos Labs Limi Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limi-upgraded-from-sell-to-hold-by-marketsmojo-on-1-dec-2025-3766973",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/HaleosLabsLimi_mojoScore_3766973.png",
        "date": "2025-12-23 10:10:29",
        "description": "Haleos Labs Limi has undergone a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial developments and valuation considerations. The pharmaceutical and biotechnology company’s assessment now indicates a more balanced outlook, influenced by changes across quality, valuation, financial trends, and technical factors."
      },
      {
        "title": "Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-lower-circuit-amid-heavy-selling-pressure-3762776",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/HaleosLabsLimit_stocks_hitting_lower_circuit_3762776.png",
        "date": "2025-12-18 15:00:10",
        "description": "Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 18 Dec 2025, hitting the lower circuit limit and registering a maximum daily loss of 5.0%. The stock closed at ₹1,232.4, marking a significant decline amid subdued investor participation and unfilled supply on the order books."
      },
      {
        "title": "Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-lower-circuit-amid-heavy-selling-pressure-3761347",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/HaleosLabsLimit_stocks_hitting_lower_circuit_3761347.png",
        "date": "2025-12-17 12:00:11",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 17 Dec 2025 as the stock hit its lower circuit limit, reflecting intense selling pressure and a maximum daily loss of 5.0%. The stock’s performance notably lagged behind its sector and broader market indices, signalling a day marked by panic selling and unfilled supply."
      },
      {
        "title": "Haleos Labs Limited Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-upgraded-to-hold-by-marketsmojo-amid-mixed-technical-and-financial-signals-3740757",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/HaleosLabsLimit_mojoScore_3740757.png",
        "date": "2025-12-02 08:58:04",
        "description": "Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation following a combination of recent financial results and technical market indicators. The company’s performance over various timeframes, alongside its valuation and technical trends, has prompted a nuanced reassessment of its investment profile."
      },
      {
        "title": "How has been the historical performance of Haleos Labs Limi?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-haleos-labs-limi-3739366",
        "imagepath": "",
        "date": "2025-12-01 23:32:30",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Examining the net sales figures, Haleos Labs Limi recorded ₹344.72 crores in the fiscal year ending March 2025, reflecting a recovery from a dip in the previous year when sales stood at ₹305.96 crores. The company’s revenue has oscillated over the years, peaking at ₹377.85 crores in March 2019 and experiencing a trough around ₹260.78 crores in March 2020. Despite these fluctuations, the firm has maintained a consistent operating profit margin, which improved to 13.07% in March 2025 from 10.17% in the prior year, signalling enhanced operational efficiency.</p>\n<p>Operating profit (PBDIT) excluding other income rose significantly to ₹45.04 crores in March 2025, up from ₹31.12 crores in March 2024. Including other income, operating profit reached..."
      },
      {
        "title": "Haleos Labs Limited Forms Golden Cross, Signalling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-forms-golden-cross-signalling-potential-bullish-breakout-3735949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/HaleosLabsLimit_goldencross_3735949.png",
        "date": "2025-11-28 18:00:35",
        "description": "Haleos Labs Limited has recently experienced a significant technical event known as the Golden Cross, where its 50-day moving average has crossed above the 200-day moving average. This development is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company."
      }
    ],
    "total": 423,
    "sid": "1002809",
    "stock_news_url": "https://www.marketsmojo.com/news/haleos-labs-limited-1002809"
  },
  "announcements": [
    {
      "details": "SMS Lifesciences India Limited has informed the Exchange regarding Board meeting held on November 14, 2019.",
      "source": "NSE",
      "caption": "SMS Lifesciences India Limited - Outcome of Board Meeting",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "SMS Lifesciences India Limited has informed the Exchange regarding 'Update on Ranitidine HCL'.",
      "source": "NSE",
      "caption": "SMS Lifesciences India Limited - Updates",
      "datetime": "04-Nov-2019"
    },
    {
      "details": "SMS Lifesciences India Limited has informed the Exchange regarding 'Certificate under regulation 74(5) of SEBI(DP)Regulations,2018'.",
      "source": "NSE",
      "caption": "SMS Lifesciences India Limited - Updates",
      "datetime": "22-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Haleos Labs Limited has declared <strong>15%</strong> dividend, ex-date: 24 Sep 25",
          "dt": "2025-09-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Haleos Labs Limited is Rated Hold by MarketsMOJO

2026-01-14 10:10:37

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Haleos Labs Limited is Rated Hold by MarketsMOJO

2026-01-03 10:10:34

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure

2025-12-26 11:00:15

Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 26 Dec 2025, hitting the lower circuit limit and registering one of the steepest single-day declines in recent times. The stock’s performance contrasted sharply with broader market indices and its sector peers, reflecting a wave of panic selling and unfilled supply on the trading floor.

Read full news article

Haleos Labs Limi Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-23 10:10:29

Haleos Labs Limi has undergone a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial developments and valuation considerations. The pharmaceutical and biotechnology company’s assessment now indicates a more balanced outlook, influenced by changes across quality, valuation, financial trends, and technical factors.

Read full news article

Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure

2025-12-18 15:00:10

Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 18 Dec 2025, hitting the lower circuit limit and registering a maximum daily loss of 5.0%. The stock closed at ₹1,232.4, marking a significant decline amid subdued investor participation and unfilled supply on the order books.

Read full news article

Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure

2025-12-17 12:00:11

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 17 Dec 2025 as the stock hit its lower circuit limit, reflecting intense selling pressure and a maximum daily loss of 5.0%. The stock’s performance notably lagged behind its sector and broader market indices, signalling a day marked by panic selling and unfilled supply.

Read full news article

Haleos Labs Limited Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:58:04

Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation following a combination of recent financial results and technical market indicators. The company’s performance over various timeframes, alongside its valuation and technical trends, has prompted a nuanced reassessment of its investment profile.

Read full news article

How has been the historical performance of Haleos Labs Limi?

2025-12-01 23:32:30

Revenue and Profitability Trends

Examining the net sales figures, Haleos Labs Limi recorded ₹344.72 crores in the fiscal year ending March 2025, reflecting a recovery from a dip in the previous year when sales stood at ₹305.96 crores. The company’s revenue has oscillated over the years, peaking at ₹377.85 crores in March 2019 and experiencing a trough around ₹260.78 crores in March 2020. Despite these fluctuations, the firm has maintained a consistent operating profit margin, which improved to 13.07% in March 2025 from 10.17% in the prior year, signalling enhanced operational efficiency.

Operating profit (PBDIT) excluding other income rose significantly to ₹45.04 crores in March 2025, up from ₹31.12 crores in March 2024. Including other income, operating profit reached...

Read full news article

Haleos Labs Limited Forms Golden Cross, Signalling Potential Bullish Breakout

2025-11-28 18:00:35

Haleos Labs Limited has recently experienced a significant technical event known as the Golden Cross, where its 50-day moving average has crossed above the 200-day moving average. This development is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company.